Efficacy of Erdafitinib

Erdafitinib (Erdafitinib) is a pan-fibroblast growth factor receptor (FGFR) inhibitor approved for the treatment of locally advanced or metastatic urothelial carcinoma in patients with FGFR3/2 predisposing alterations that have progressed after platinum-containing chemotherapy. The role of erdafitinib in patients with FGFR-altered metastatic urothelial carcinoma who progress during or after treatment with checkpoint inhibitors (anti-programmed cell death protein 1 [PD-1] or anti-programmed death ligand 1 [PD-L1] drugs) is unclear.

A total of266 patients were randomly assigned: 136 to the erdafitinib group and 130 to the chemotherapy group. The median follow-up time was 15.9 months. The median overall survival time of the erdafitinib group was significantly longer than that of the chemotherapy group, being 12.1 months and 7.8 months respectively; the median progression-free survival time of the erdafitinib group was also longer than that of the chemotherapy group, being 5.6 months and 2.7 months respectively. Treatment-related adverse events leading to death were less common with erdafitinib compared with chemotherapy (0.7% vs. 5.4%, respectively). The study results show that the overall survival of erdafitinib treatment is significantly longer than that of chemotherapy. Changes in FGFR after previous anti-PD-1 or anti-PD-L1 treatment.

The original version of erdafitinib has not yet been launched in China, so it cannot be covered by medical insurance. The original version of erdafitinib currently sold in Hong Kong may cost more than 20,000 yuan per box of specifications 4mg*14 tablets (the price may fluctuate due to exchange rates). Cheaper erdafitinib generic drugs produced by other pharmaceutical factories are also sold overseas. The pharmaceutical ingredients are basically the same as those of the original drug. For example, the price of 4mg*60 tablets produced by a Bangladeshi pharmaceutical factory may be more than 3,000 yuan per box (the price may fluctuate due to exchange rates).